Cargando…
The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials
Background: With the development of the sentinel node technique in early-stage cervical cancer, it is imperative to define the clinical significance of micrometastases (MICs) and isolated tumor cells (ITCs). Methods: We included all patients who participated in the Senticol 1 and Senticol 2 studies....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281258/ https://www.ncbi.nlm.nih.gov/pubmed/32344814 http://dx.doi.org/10.3390/cancers12051061 |
_version_ | 1783543881170681856 |
---|---|
author | Guani, Benedetta Balaya, Vincent Magaud, Laurent Lecuru, Fabrice Mathevet, Patrice |
author_facet | Guani, Benedetta Balaya, Vincent Magaud, Laurent Lecuru, Fabrice Mathevet, Patrice |
author_sort | Guani, Benedetta |
collection | PubMed |
description | Background: With the development of the sentinel node technique in early-stage cervical cancer, it is imperative to define the clinical significance of micrometastases (MICs) and isolated tumor cells (ITCs). Methods: We included all patients who participated in the Senticol 1 and Senticol 2 studies. We analyzed the factors associated with the presence of low-volume metastasis, the oncological outcomes of patients with MIC and ITC and the correlation of recurrences and risk factors. Results: Twenty-four patients (7.5%) had low-volume metastasis. The risk factors associated with the presence of low-volume metastasis were a higher stage (p = 0.02) and major stromal invasion (p = 0.01) in the univariate analysis. The maximum specificity and sensitivity were found at a cutoff of 8 mm of stromal invasion. In multivariate analysis, the higher stage (p = 0.02) and the positive lymphovascular space invasion (p = 0.02) were significantly associated with the MIC and ITC. Patients with low-volume metastasis had similar disease-free survival (DFS) (92.7%) to node-negative patients (93.6%). The addition of adjuvant treatment in presence of low-volume metastasis did not modify the DFS. Conclusions: These results confirm our previous analysis of Senticol 1: the presence of low-volume metastasis did not decrease the DFS in early-stage cervical cancer patients. |
format | Online Article Text |
id | pubmed-7281258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72812582020-06-15 The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials Guani, Benedetta Balaya, Vincent Magaud, Laurent Lecuru, Fabrice Mathevet, Patrice Cancers (Basel) Article Background: With the development of the sentinel node technique in early-stage cervical cancer, it is imperative to define the clinical significance of micrometastases (MICs) and isolated tumor cells (ITCs). Methods: We included all patients who participated in the Senticol 1 and Senticol 2 studies. We analyzed the factors associated with the presence of low-volume metastasis, the oncological outcomes of patients with MIC and ITC and the correlation of recurrences and risk factors. Results: Twenty-four patients (7.5%) had low-volume metastasis. The risk factors associated with the presence of low-volume metastasis were a higher stage (p = 0.02) and major stromal invasion (p = 0.01) in the univariate analysis. The maximum specificity and sensitivity were found at a cutoff of 8 mm of stromal invasion. In multivariate analysis, the higher stage (p = 0.02) and the positive lymphovascular space invasion (p = 0.02) were significantly associated with the MIC and ITC. Patients with low-volume metastasis had similar disease-free survival (DFS) (92.7%) to node-negative patients (93.6%). The addition of adjuvant treatment in presence of low-volume metastasis did not modify the DFS. Conclusions: These results confirm our previous analysis of Senticol 1: the presence of low-volume metastasis did not decrease the DFS in early-stage cervical cancer patients. MDPI 2020-04-25 /pmc/articles/PMC7281258/ /pubmed/32344814 http://dx.doi.org/10.3390/cancers12051061 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Guani, Benedetta Balaya, Vincent Magaud, Laurent Lecuru, Fabrice Mathevet, Patrice The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials |
title | The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials |
title_full | The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials |
title_fullStr | The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials |
title_full_unstemmed | The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials |
title_short | The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials |
title_sort | clinical impact of low-volume lymph nodal metastases in early-stage cervical cancer: the senticol 1 and senticol 2 trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281258/ https://www.ncbi.nlm.nih.gov/pubmed/32344814 http://dx.doi.org/10.3390/cancers12051061 |
work_keys_str_mv | AT guanibenedetta theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT balayavincent theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT magaudlaurent theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT lecurufabrice theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT mathevetpatrice theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT guanibenedetta clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT balayavincent clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT magaudlaurent clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT lecurufabrice clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials AT mathevetpatrice clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials |